|
KMID : 0043320190420040293
|
|
Archives of Pharmacal Research
2019 Volume.42 No. 4 p.293 ~ p.304
|
|
|
Targets of monoclonal antibodies for immunological diseases
|
|
Yoo Seon-Min
Chung Sung-Hyun
|
|
|
Abstract
|
|
|
|
Immunological disorders such as allergy, autoimmune diseases, auto-inflammatory syndromes and immunological deficiency syndromes are difficult to treat with chemical drugs. Recently, many monoclonal antibodies targeting various molecules including interleukin, tumor necrosis factor-α, cluster of differentiation, integrins, complement C5 and B lymphocyte stimulator are clinically available and give a hope to patients suffering from these intractable diseases. Here, we selected twenty-seven monoclonal antibodies approved by US FDA since 1997 and they are classified according to their target molecules. Although these biomedicines possessed some restrictions such as high cost and susceptible to infectious disease, these drawbacks can be overcome through cost-cutting innovations including biosimilars and careful monitoring. New targets are emerging rapidly and more effective biomedicines with acceptable side effects are in the pipeline for next decade.
|
|
|
KEYWORD
|
|
|
Biomedicines, Biosimilar, Monoclonal antibody, Immunological disorder
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|